Posted by Michael Wonder on 23 Nov 2015
Vertex Receives EU approval for Orkambi (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation
20 November 2015 - Vertex will now begin the country-by-country reimbursement approval process across the European Union.
For more details, go to: http://investors.vrtx.com/releases.cfm
